Objectives: Repetitive transcranial magnetic stimulation [rTMS] of the cerebral cortex has been tested as a treatment tool for various neurological and psychiatric diseases and other painful disorders. Our objectives were to determine whether high-frequency rTMS applied to the primary motor cortex could decrease pain intensity and influence the quality of life in patients with fibromyalgia syndrome [FMS]. Design: Fifty two patients with FMS were randomized to real [n = 27] or sham [n = 25] treatment groups. Ten consecutive sessions of rTMS were given to each of the patients. All patients were evaluated with the Structured Clinical Interview from the Diagnostic and Statistical Manual of Mental Disorders before treatment. The level of pain and the mood status were assessed with a visual analog scale and the Montgomery Asberg Rating Scale, respectively. The Turkish version of the World Health Quality of Life-BREF instrument was used to evaluate the quality of life. Results: The decrease of pain scale scores was found to be significantly greater among the real rTMS group than among those in the sham group [p < 0.001]. Also the life quality physical subscale score improvement was significantly greater among those in the real rTMS therapy group than among those in the sham treatment group [p < 0.001]. A strong relationship was found betweeen the decrease of pain levels in the real rTMS treated patients and the life quality physical subscale score improvement [R2 = 0.419 and p < 0.001]. Conclusions: These findings suggest that high-frequency rTMS application to the primary motor cortex could have an analgesic effect. Therefore, rTMS may be an alternative therapeutic option in FMS.
Migraine is a type of primary headache caused by changes in the trigeminal system and has been reported to be associated with neurovascular inflammation of cerebral and extracerebral vessels. It is known that inflammation is an important process in the pathogenesis of migraine. It has been shown that the molecules of visinin-like protein 1 (Vilip-1), YKL-40, lipocalin-2 and interleukin (IL)-23 play a role in the inflammatory process. Our aim is to investigate the role of this molecule in the metabolic pathway of migraine disease. Fifty migraine patients with and without aura in the interictal period were included in the study. Vilip-1, YKL-40, lipocalin-2, and IL-23 levels were measured by ELISA method. Serum vilip-1, YKL-40, lipocalin-2, and IL-23 levels were found to be significantly higher in migraine patients compared to the control group. We found that this molecule increased significantly in migraine subgroups compared to the control group (p < 0.001). A positive significant correlation was found between vilip-1 level and YKL-40 and lipocalin-2 levels in migraine patients. In addition, a positive correlation was observed between visual analogue scale score, number of days with pain and vilip-1 level (p < 0.01). The results of our study showed that activation of inflammatory mediators may play a role in the pathogenesis of migraine disease. In addition, our study is valuable in that inflammatory molecules are high in the interictal period and these biomarkers have never been analyzed in migraine patients. However, we still believe that larger studies are needed to explain the role of vilip-1, YKL-40, lipocalin-2, and IL-23 in the molecular mechanism of migraine disease.
Background Idiopathic intracranial hypertension (IIH) is characterized by increased cerebrospinal fluid (CSF) pressure of unknown cause. It has been suggested that the inflammatory process plays a role in the pathophysiology of the disease. Sortilin-1, lipocalin-2, autotaxin, decorin, and interleukin-33 (IL-33) are among the factors involved in inflammatory processes. Objective To investigate the CSF levels of sortilin-1, lipocalin-2, autotaxin, decorin, and IL-33 in patients with IIH. Methods A total of 24 IIH patients and 21 healthy controls were included in the study. Demographic characteristics of the patients and of the control group as well as CSF pressures were evaluated. Sortilin-1, lipocalin-2, autotaxin, decorin and IL-33 levels in the CSF were measured. Results The CSF levels lipocalin-2, sortilin-1, autotaxin, IL-33 and CSF pressure were significantly higher in the patients group compared with the control group (p < 0.001). Decorin levels were reduced in patients (p < 0.05). There was no correlation between the autotaxin and IL-33 levels and age, gender, CSF pressure, and body mass index. The results of our study showed that inflammatory activation plays an important role in the development of the pathophysiology of IIH. In addition, the fact that the markers used in our study have never been studied in the etiopathogenesis of IIH is important in explaining the molecular mechanism of this disease. Conclusion Studies are needed to evaluate the role of these cytokines in the pathophysiology of the disease. It is necessary to evaluate the effects of these molecules on this process.
30 April 2023 in Interdisciplinary Medical Journal
Objective: Epilepsy is a neurological disease characterized by recurrent seizures. The underlying pathophysiological mechanisms in epilepsy are not fully known. Our aim is to investigate the relationship between serum adipocytokine and interleukin (IL)-18 levels in epilepsy patients receiving and not receiving antiepileptic therapy. Method: Our study was established as three groups. I: Epilepsy patients receiving antiepileptic therapy (n=30), II: Newly diagnosed epilepsy patients (n=30) and III: Control group (n=30). Serum adipocytokine and IL-18 levels were measured by enzyme-linked immunoassorbent assay method. Results: It was determined that serum adipocytokine and IL-18 levels were increased in epilepsy patients who received topiramate treatment and did not receive antiepileptic therapy compared to the control group. Serum glucose, total protein, cholesterol and albumin concentrations of patients who received antiepileptic treatment were decreased compared to the control group (p0.05). It was found that the body mass index (BMI) ratio of epilepsy patients who received antiepileptic treatment decreased and was significant compared to the control group and the group that did not receive treatment (p<0.01). Conclusion: In our study, it was shown that serum adipocytokine and IL-18 levels were increased in epilepsy patients who received and did not receive antiepileptic therapy. Findings from this study suggest that adipocytokine and IL-18 may be useful markers for the inflammatory process of epileptogenesis.
15 December 2021 in Journal of Drug Delivery and Therapeutics
Objective: Alzheimer's disease (AD) is the most common form of dementia, can be created in experimental models by using toxins. Possible therapeutic effects of secondary metabolites Rosmarinic (RA) and Oleanolic acids (OA) obtained from Salvia species (sage) were investigated using histopathological and immunohistochemical tecniques in experimental Alzheimer's-like dementia model induced by scopolamine. Study Design: Male BALB/c mice (n: 48) of 3-4 weeks old, divided into 6 groups; control received only saline(i.p.) for 21 days, scopolamine group received 3 mg/kg of scopolamine (i.p.) between 8-21th days. Scopolamine + RA group received 5 mg/kg RA (i.p.) between days 0 and 21 and 3 mg/kg of scopolamine (i.p.) between 8-21th days. Scopolamine + OA group received 5 mg/kg of OA (i.p.) between days of 0-21 and 3 mg/kg of scopolamine (i.p.) between 8-21th days. RA group received 5 mg/kg RA (i.p.) between 0-21th days. OA group received 5 mg/kg of OA (i.p.) between 0-21th days. Animals were sacrificed under anesthesia, brain tissues were excised and placed in 10% formaldehyde, embedded in paraffin wax. 5 µm sections were cut, stained for histopathological examinations. Immunoreactivity for Beta-amyloid accumulation was observed. ImageJ 153 software was used to analyze IHC figures. Positive signaling for DAB density was calculated, ANOVA test with the post hoc dunnett's or tukey test were applied, p<0.05 was considered statistically significant. Results: In scopolamine+RA treated group, tissue degeneration was less compared to the scopolamine group. Scopolamine+OA group revealed signs of pyknosis in neurons. The amyloid beta immunoexpression was positive in scopolamine group partially positive in scopolamine+OA group but, negative in RA treated scopolamine group. Intensity of signal in scopolamine group was statistically increased compared to control (p=0.0102). Intensity of signal was reduced in Scopolamine+RA and Scopolamine+OA groups, was statistically significant (p=0.0281 and p=0.0362, respectively). Conclusion: We suggest that pretreatment of RA and OA decreased beta amyloid formation and ameliorated tissue structure but, further studies with different methods are needed to be commercially available. Keywords: Scopolamine, dementia, Rosmarinic acid, Oleanolic acid, histopathology, Amyloid beta
Background: This is the first study to focus exclusively on a pure ischemic stroke cohort, exploring serum glutamine levels and their association with oxidative stress markers and clinical outcomes. Methods: 50 patients diagnosed with ischemic stroke were included in our study. We used methods such as LC-MS/MS to measure glutamine levels with high accuracy. Oxidative stress markers, including total antioxidant capacity (TAC) and total oxidant status (TOS), were also analyzed. Stroke severity was assessed using the National Institutes of Health Stroke Scale (NIHSS), and functional outcomes were evaluated using the modified Rankin Scale (mRS) at 90 days. Results: Serum glutamine levels varied significantly based on stroke severity. Patients with NIHSS ≥16 demonstrated significantly lower glutamine levels compared to those with NIHSS 16.